Alexander Maxwell
Value, growth, long-term horizon, biotech

Vanda Pharmaceuticals: A Small-Cap Biotech With A Pipeline Allowing For Long-Term Growth

Vanda Pharmaceuticals (NASDAQ:VNDA) has a very promising pipeline, which will help long-term oriented investors. Vanda has a pipeline that will set it up for success, as well as some very promising drugs. There are a mix of medium and long-term catalysts that will help Vanda to create long-term share price growth for its shareholders. Below is a graphic of Vanda's Pipeline:

(click to enlarge)


Fanapt is a drug that is already approved in the United States. It is partnered with both Titan Pharmaceuticals (OTCQB:TTNP) and Novartis (NYSE:NVS) in the United States. Currently, Vanda receives a 10% royalty on Novartis net sales of the drug. While this revenue has not been very substantial over...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details